Description
Introduction
Active pharmaceutical ingredient (API) is a biologically active pharmaceutical drug. API can be obtained by a synthetic process or from natural sources. The increasing occurrence of chronic diseases, rising acceptance, and uptake of pharmaceuticals, growth in abbreviated new drug applications (ANDA), and the growing importance of generics are expected to drive market growth. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular diseases in 2017. However, stringent regulatory policies and adverse drug price control policies across numerous countries may hamper the growth of the market.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023. In 2016, the market was led by the Americas with a 40.7% share, followed by Europe and Asia-Pacific with shares of 27.0% and 24.8%, respectively. The increasing burden of chronic diseases has been observed in different parts of the world which has upsurge the growth of the market.
The global active pharmaceutical ingredients market is segmented by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region.
The global active pharmaceutical ingredients market, by manufacturing process, is segmented into captive manufacturing and contract manufacturing.
The global active pharmaceutical ingredients market, by type of synthesis, is segmented into synthetic and biotech.
The global active pharmaceutical ingredients market, by API formulation, is segmented into generic API and innovative API.
By application, the global active pharmaceutical ingredients market is segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others.
By molecule, the global active pharmaceutical ingredients market is segmented into small molecule and large molecule.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
Key Players
Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company, and Teva Pharmaceutical Industries Ltd, and others.
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the active pharmaceutical ingredients market
• To provide insights into factors affecting the market growth
• To analyze the global active pharmaceutical ingredients market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to current market size and future perspective
• To provide country-level analysis of the market for segments by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the active pharmaceutical ingredients market
Target Audience
• Pharmaceutical and Biotechnology Companies
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global active pharmaceutical ingredients market is expected to reach USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
• On the basis of manufacturing process, the captive manufacturing segment is expected to account for the largest market share at a CAGR of 4.78% by 2023
• Based on type of synthesis, the synthetic segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• Based on API formulation, the generic API segment is expected to account for the largest market share at a CAGR of 4.62% by 2023
• Based on application, the cardiovascular disease segment is expected to account for the largest market share at a CAGR of 3.74% by 2023
• Based on molecule, the small molecule segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• The Americas is expected to hold the largest share of the global active pharmaceutical ingredients market at a CAGR of 4.74% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 5.27% by 2023
Regional Analysis
• Americas
o North America
US
Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa
Table of Contents
Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References
1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References
